Workflow
BERRY GENOMICS(000710)
icon
Search documents
贝瑞基因(000710) - 2014 Q2 - 季度财报
2014-08-29 16:00
Financial Performance - The company's operating revenue for the first half of 2014 was CNY 157,054,977.84, representing a 5.91% increase compared to CNY 148,292,347.35 in the same period last year[20]. - The net profit attributable to shareholders of the listed company was a loss of CNY 4,605,072.47, a decrease of 71.20% from a loss of CNY 2,689,918.87 in the previous year[20]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 416,052.78, an increase of 115.41% compared to a loss of CNY 2,699,197.31 in the same period last year[20]. - The operating profit for the first half of 2014 was a loss of CNY 4,738,100, a decrease of 75.27% compared to the previous year[28]. - The company reported a net loss of ¥91,827,417.03, worsening from a loss of ¥87,222,344.56 in the previous period[110]. - The net profit for the current period is -¥4.48 million, worsening from -¥2.57 million in the previous period, reflecting ongoing financial challenges[119]. Cash Flow and Liquidity - The net cash flow from operating activities was a negative CNY 20,067,634.72, which is a decline of 41.84% from a negative CNY 14,148,502.33 in the previous year[20]. - The cash flow from operating activities was negative at -¥20,067,634.72, worsening by 41.84% compared to -¥14,148,502.33 in the previous year[30]. - The net cash flow from operating activities is -¥20.07 million, a decline from -¥14.15 million in the previous period, indicating increased cash outflows[122]. - The net cash flow from investment activities was 1,200,715.08 CNY, a significant improvement from -45,974,833.29 CNY in the previous period[126]. - The ending balance of cash and cash equivalents was 17,231,510.12 CNY, down from 12,975,086.49 CNY in the previous period[127]. Assets and Liabilities - The total assets at the end of the reporting period were CNY 422,802,306.59, reflecting a 3.10% increase from CNY 410,084,460.18 at the end of the previous year[20]. - Total liabilities rose to ¥306,478,921.39, up from ¥289,086,709.44, indicating a 6.5% increase[110]. - The company's equity attributable to shareholders decreased to ¥110,834,010.80 from ¥115,439,083.27, a decline of 4.2%[110]. - The total owner's equity at the end of the current period is CNY 112,295,470, down from CNY 116,772,850 at the beginning of the year[135]. Market and Operational Strategy - The company is focused on expanding new markets and improving internal management despite facing macroeconomic pressures and increased competition[28]. - The company did not disclose any future development plans or strategies in its public documents[31]. - The company has made commitments regarding the restructuring of Tianxing Instrument to enhance its core competitiveness amid operational difficulties[84]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period is 13,657[94]. - The largest shareholder, Chengdu Tianxing Instrument (Group) Co., Ltd., holds 58.86% of the shares, totaling 89,002,000 shares, with 32,310,000 shares pledged[95]. - There were no changes in the controlling shareholder or actual controller during the reporting period[97]. Related Party Transactions - The company engaged in related party transactions amounting to 6,882.92 million yuan, with various transactions including sales and purchases at market prices[64][65]. - The related party transactions did not have a significant impact on the company's operating results and financial status[69]. Compliance and Governance - There were no significant litigation or arbitration matters during the reporting period[56]. - The company confirmed the normal performance of commitments made by controlling shareholders regarding independence and avoidance of competition[81][82]. - There are no penalties or rectification measures reported during the reporting period, indicating compliance with regulations[86]. Accounting Policies - The company adheres to the accounting standards set by the Ministry of Finance, ensuring that the financial statements accurately reflect its financial position as of June 30, 2014[142]. - The company uses RMB as its functional currency for accounting purposes[144]. - The company recognizes revenue from the sale of goods when the main risks and rewards of ownership are transferred to the buyer, and the economic benefits related to the sale can be reliably measured[187].
贝瑞基因(000710) - 2014 Q1 - 季度财报
2014-04-27 16:00
Financial Performance - The company's operating revenue for Q1 2014 was ¥53,871,913.31, a decrease of 21.25% compared to ¥68,406,407.56 in the same period last year[8] - The net profit attributable to shareholders was a loss of ¥1,499,277.09, showing a slight improvement of 3.3% from a loss of ¥1,550,374.78 in the previous year[8] - The net cash flow from operating activities was negative at ¥24,638,589.25, a significant decline of 715.69% compared to a positive cash flow of ¥4,001,753.38 in the same period last year[8] - Total assets at the end of the reporting period were ¥389,877,086.10, down 4.93% from ¥410,084,460.18 at the end of the previous year[8] - The weighted average return on net assets was -1.31%, slightly improved from -1.32% in the previous year[8] - Tax and additional fees decreased by 68.67% year-on-year, mainly due to reduced product gross margins[15] - Financial expenses increased by 53.9% year-on-year, primarily due to higher interest expenses[15] - Investment income increased by 100% year-on-year, mainly from investments in Chengdu Tianxing Shantian Automotive Parts Co., Ltd.[15] Shareholder Information - The number of shareholders at the end of the reporting period was 13,881, with the largest shareholder holding 58.86% of the shares[11] Operational Independence - The company is committed to ensuring the independence of its personnel, assets, business, and finances, with ongoing compliance with the commitments made during the acquisition process[18] - The company has established an independent financial department and accounting system, ensuring that it operates independently from its controlling shareholders[19] - The company guarantees that its financial personnel do not hold positions in the controlling shareholder's subsidiaries, ensuring financial independence[19] - The company has committed to maintaining an independent operational capability, with a focus on market-driven sustainable operations[19] - The company has not invested in any businesses that compete with its main operations in motorcycle and automotive parts design, production, and sales[19] - The company has a commitment to avoid any business activities that may compete with its subsidiaries, ensuring no conflict of interest[19] - The company has made a long-term commitment to maintain the independence of its board and management decisions[18] Market Expansion and Restructuring - The company is actively working on the restructuring of its assets, including resolving issues related to property and land rights[19] - The company is in the process of expanding its market presence and is actively pursuing business opportunities that align with its core operations[19] - The company is currently engaged in ongoing discussions regarding potential acquisitions to enhance its market position[19] - Chengdu Tianxing Instrument Co., Ltd. reported that the main business involves the design, production, processing, and sales of motorcycle and automotive parts[20] - The company has completed land leveling, drilling, and design for a new factory area, with a construction period of 2-3 years[20] - Tianxing Instrument is facing significant operational difficulties and plans to adjust its business structure to enhance core competitiveness[22] - The company has committed to resolving the separation of property and land rights within 12 months after the completion of the current acquisition[22] Investment Activities - The company has not made any securities investments during the reporting period, with no shares held[25] - No derivative investments were reported during the period, with a total initial investment of 0 and a year-end investment amount also at 0, representing 0% of the company's net assets[26] - The company did not disclose any information regarding the approval dates for derivative investments by the board or shareholders[26] Profit Warning - There is a warning regarding the potential for significant changes in net profit for the first half of 2014 compared to the previous year[25]
贝瑞基因(000710) - 2013 Q4 - 年度财报
2014-04-18 16:00
Financial Performance - The company's operating revenue for 2013 was ¥262,234,824.69, a decrease of 20.79% compared to ¥331,077,628.33 in 2012[22]. - The net profit attributable to shareholders was -¥6,156,854.77, representing a significant decline of 1,666.69% from a profit of ¥392,984.52 in the previous year[22]. - The net cash flow from operating activities decreased by 67.62% to ¥15,627,955.37, down from ¥48,265,432.09 in 2012[22]. - The basic earnings per share were -¥0.0407, a drop of 1,665.38% compared to ¥0.0026 in 2012[22]. - The weighted average return on net assets was -5.36%, a decline from 0.34% in the previous year[22]. - The net profit attributable to the parent company was CNY -615.69 million, a decline of 1,666.69% year-on-year[32]. - The company reported a net loss of RMB 87,222,344.56 for the year, compared to a loss of RMB 81,065,489.79 in the previous year, indicating a worsening of approximately 7.3%[191]. - The net loss for the period was CNY 6,229,471.78, compared to a net profit of CNY 221,802.64 in the previous period, indicating a significant decline in profitability[197]. Assets and Liabilities - Total assets increased by 20.25% to ¥410,084,460.18 at the end of 2013, up from ¥341,017,987.60 at the end of 2012[22]. - The total assets of Chengdu Tianxing Instrument Co., Ltd. as of December 31, 2013, amounted to RMB 410,084,460.18, an increase from RMB 341,017,987.60 at the beginning of the year, representing a growth of approximately 20.3%[190]. - The company's total liabilities increased to RMB 289,086,709.44 from RMB 217,337,616.16, reflecting a rise of about 32.9%[191]. - Total liabilities rose to CNY 288,287,258.44, up from CNY 217,288,165.16, marking an increase of 32.8%[195]. - The total owner's equity decreased to RMB 120,997,750.74 from RMB 123,680,371.44, indicating a decline of approximately 2.2%[191]. - Owner's equity decreased to CNY 116,772,859.18 from CNY 120,179,898.18, a decline of 2.9%[195]. Cash Flow - The cash flow from operating activities decreased by 67.62% year-on-year, primarily due to increased cash payments related to operating activities[44]. - The company's cash and cash equivalents decreased by CNY 18,826,800.62, a decline of 170.77% compared to the previous year[44]. - The company's cash and cash equivalents net increase decreased by 170.77% year-on-year, mainly due to increased cash payments for Tianxing Shantian equity and increased cash from bank loans[45]. - Cash and cash equivalents at the end of 2013 were RMB 101,214,424.58, up from RMB 86,665,225.20, marking an increase of about 16.5%[189]. Investment Activities - Investment cash inflow increased by 345.04% year-on-year, mainly due to an increase in cash received related to other investment activities[45]. - Investment cash outflow increased by 182.51% year-on-year, primarily due to increased cash payments for Tianxing Shantian equity[45]. - Net cash flow from investment activities decreased by 180.67% year-on-year, mainly due to increased cash payments for Tianxing Shantian equity[45]. - Net cash flow from financing activities increased by 484.61% year-on-year, primarily due to increased cash received from bank loans[45]. Business Operations - The company has detailed risk factors that may affect its future development in the report[13]. - The decline in performance is attributed to rising raw material and labor costs, alongside a decrease in production scale and product sales prices[81]. - The company has not made any changes to its main business since its listing[19]. - The company’s main business revenue accounted for 95.19% of total operating revenue, amounting to CNY 249,627,776.26[33]. - The company’s total operating costs were CNY 229,426,208.40, with main business costs at CNY 217,410,235.74, accounting for 94.87% of total costs[39]. - The company’s financial expenses increased by 97.55% compared to the previous year, mainly due to higher interest expenses[42]. - The company’s gross profit margin for automotive parts was 82.8%, up from 66.91% in the previous year, indicating a 15.89% increase[39]. Research and Development - The company’s R&D expenditure was CNY 12.73 million, representing 10.52% of net assets and 4.85% of operating revenue[43]. - The company developed 107 new products during the reporting period, including 61 automotive instruments, 31 motorcycle instruments, and 13 sensors[59]. Shareholder Information - The total number of shares is 151,200,000, with 100% being unrestricted shares[135]. - The largest shareholder, Chengdu Tianxing Instrument (Group) Co., Ltd., holds 58.86% of the shares, totaling 89,002,000 shares[140]. - The total number of shareholders at the end of the reporting period is 13,681[140]. - The company has not distributed cash dividends in the past three years due to negative retained earnings, with the latest net profit for 2013 reported at -6,156,854.77 yuan[91][89]. Corporate Governance - The company’s governance structure complies with the requirements of the Company Law and relevant regulations from the China Securities Regulatory Commission[165]. - The company has established a management system for insider information to prevent misuse of sensitive information[166]. - The company maintains independence from its controlling shareholder in business, personnel, assets, organization, and finance, ensuring a complete and independent operational structure[175]. - The company has established a performance evaluation and incentive system for senior management, with monthly checks and annual assessments conducted[177]. - No significant deficiencies in internal control over financial reporting were identified during the reporting period[181]. Future Outlook - The company aims for a certain percentage increase in revenue, total profit, and net profit for the fiscal year 2014[83]. - The focus will be on expanding automotive instrument products, particularly targeting B and C class vehicles, while stabilizing the micro vehicle market and developing electronic motorcycle instruments[83]. - The company plans to enhance quality management and control processes to reduce market return losses and improve user satisfaction[83]. - There is a commitment to strengthen independent innovation and technical breakthroughs, with an emphasis on optimizing the development organization and increasing talent acquisition[83]. - The company is currently facing operational difficulties and is seeking external assistance to restructure its business model and enhance core competitiveness[126].